Business Description
ADC Therapeutics SA
NAICS : 325412
SIC : 2834
ISIN : CH0499880968
Total Employee Number:
193Description
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.98 | |||||
Equity-to-Asset | -0.74 | |||||
Debt-to-Equity | -0.54 | |||||
Debt-to-EBITDA | -1.41 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -7.64 | |||||
Beneish M-Score | 0.92 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -38 | |||||
3-Year EBITDA Growth Rate | 20.5 | |||||
3-Year EPS without NRI Growth Rate | 11.8 | |||||
3-Year FCF Growth Rate | 14.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 60.51 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 39.86 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.69 | |||||
9-Day RSI | 56.29 | |||||
14-Day RSI | 43.6 | |||||
3-1 Month Momentum % | -74.07 | |||||
6-1 Month Momentum % | -69.34 | |||||
12-1 Month Momentum % | -64.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.09 | |||||
Quick Ratio | 4.02 | |||||
Cash Ratio | 3.42 | |||||
Days Inventory | 617.72 | |||||
Days Sales Outstanding | 130.03 | |||||
Days Payable | 474.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16 | |||||
Shareholder Yield % | -21.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.71 | |||||
Operating Margin % | -131.69 | |||||
Net Margin % | -173.02 | |||||
EBITDA Margin % | -104.65 | |||||
FCF Margin % | -144.72 | |||||
OCF Margin % | -144.68 | |||||
ROA % | -45.71 | |||||
ROIC % | -298.01 | |||||
3-Year ROIIC % | -27.85 | |||||
ROC (Joel Greenblatt) % | -1646.38 | |||||
ROCE % | -35.87 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.36 | |||||
EV-to-EBIT | -0.69 | |||||
EV-to-EBITDA | -0.7 | |||||
EV-to-Revenue | 0.73 | |||||
EV-to-Forward-Revenue | 0.67 | |||||
EV-to-FCF | -0.51 | |||||
Price-to-GF-Value | 0.65 | |||||
Earnings Yield (Greenblatt) % | -144.93 | |||||
FCF Yield % | -66.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ADCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
ADC Therapeutics SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 79.175 | ||
| EPS (TTM) ($) | -1.05 | ||
| Beta | 3.7581 | ||
| 3-Year Sharpe Ratio | 0.29 | ||
| 3-Year Sortino Ratio | 0.62 | ||
| Volatility % | 83.98 | ||
| 14-Day RSI | 43.6 | ||
| 14-Day ATR ($) | 0.13124 | ||
| 20-Day SMA ($) | 1.191 | ||
| 12-1 Month Momentum % | -64.31 | ||
| 52-Week Range ($) | 0.7796 - 4.98 | ||
| Shares Outstanding (Mil) | 127.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ADC Therapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ADC Therapeutics SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:30 | In 114 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 113 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:30 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 23 days | ||
| General meeting for 2026 | 2026-06-03 10:00 | 3.17 (-5.65%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 08:30 | 3.83 (+1.32%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 3.83 (+1.32%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 08:30 | 4.23 (+4.96%) | ||
| Annual report for 2025 | 2026-03-10 | 4.23 (+4.96%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 4.23 (+4.96%) |
Show
Entries
ADC Therapeutics SA Frequently Asked Questions
What is ADC Therapeutics SA(ADCT)'s stock price today?
The current price of ADCT is $1.36. The 52 week high of ADCT is $4.98 and 52 week low is $0.78.
When is next earnings date of ADC Therapeutics SA(ADCT)?
The next earnings date of ADC Therapeutics SA(ADCT) is 2026-08-12 Est..
Does ADC Therapeutics SA(ADCT) pay dividends? If so, how much?
ADC Therapeutics SA(ADCT) does not pay dividend.
Guru Commentaries on NYSE:ADCT
No articles.
Press Release
Articles on ADC Therapeutics SA
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers